BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 19836781)

  • 1. Phosphatidylinositol-3-kinase/Akt signaling pathway and kidney cancer, and the therapeutic potential of phosphatidylinositol-3-kinase/Akt inhibitors.
    Porta C; Figlin RA
    J Urol; 2009 Dec; 182(6):2569-77. PubMed ID: 19836781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
    Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K-Akt pathway in kidney cancer.
    Park JY; Lin PY; Weiss RH
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):863-70. PubMed ID: 17555396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug discovery approaches targeting the PI3K/Akt pathway in cancer.
    Garcia-Echeverria C; Sellers WR
    Oncogene; 2008 Sep; 27(41):5511-26. PubMed ID: 18794885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.
    Granville CA; Memmott RM; Gills JJ; Dennis PA
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):679-89. PubMed ID: 16467077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises.
    Yap TA; Garrett MD; Walton MI; Raynaud F; de Bono JS; Workman P
    Curr Opin Pharmacol; 2008 Aug; 8(4):393-412. PubMed ID: 18721898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Topics in mTOR pathway and its inhibitors].
    Dreyer C; Sablin MP; Faivre S; Raymond E
    Bull Cancer; 2009 Jan; 96(1):87-94. PubMed ID: 19211363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer.
    Kim D; Cheng GZ; Lindsley CW; Yang H; Cheng JQ
    Curr Opin Investig Drugs; 2005 Dec; 6(12):1250-8. PubMed ID: 16370391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial comment.
    Oya M
    J Urol; 2009 Dec; 182(6):2577. PubMed ID: 19836782
    [No Abstract]   [Full Text] [Related]  

  • 10. [Correlation of PI3K-Akt signal pathway to apoptosis of tumor cells].
    Huang XL; Cui GH; Zhou KY
    Ai Zheng; 2008 Mar; 27(3):331-6. PubMed ID: 18334129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone-related protein induces cell survival in human renal cell carcinoma through the PI3K Akt pathway: evidence for a critical role for integrin-linked kinase and nuclear factor kappa B.
    Agouni A; Sourbier C; Danilin S; Rothhut S; Lindner V; Jacqmin D; Helwig JJ; Lang H; Massfelder T
    Carcinogenesis; 2007 Sep; 28(9):1893-901. PubMed ID: 17468516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From Rapa Nui to rapamycin: targeting PI3K/Akt/mTOR for cancer therapy.
    Georgakis GV; Younes A
    Expert Rev Anticancer Ther; 2006 Jan; 6(1):131-40. PubMed ID: 16375650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
    Generali D; Fox SB; Brizzi MP; Allevi G; Bonardi S; Aguggini S; Milani M; Bersiga A; Campo L; Dionisio R; Vergoni F; Giardini R; Dogliotti L; Bottini A; Harris AL; Berruti A
    Clin Cancer Res; 2008 May; 14(9):2673-80. PubMed ID: 18451231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K/Akt partially leads to the inhibition of PrP(C)-induced drug resistance in gastric cancer cells.
    Liang J; Ge F; Guo C; Luo G; Wang X; Han G; Zhang D; Wang J; Li K; Pan Y; Yao L; Yin Z; Guo X; Wu K; Ding J; Fan D
    FEBS J; 2009 Feb; 276(3):685-94. PubMed ID: 19143835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting mTOR signaling in lung cancer.
    Marinov M; Fischer B; Arcaro A
    Crit Rev Oncol Hematol; 2007 Aug; 63(2):172-82. PubMed ID: 17540577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential roles of phosphatidylinositol 3-kinase/akt pathway in retinal ganglion cell survival in rats with or without acute ocular hypertension.
    Huang Y; Cen LP; Luo JM; Wang N; Zhang MZ; van Rooijen N; Pang CP; Cui Q
    Neuroscience; 2008 Apr; 153(1):214-25. PubMed ID: 18358617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
    Menges CW; McCance DJ
    Oncogene; 2008 May; 27(20):2934-40. PubMed ID: 18059341
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.